Le Lézard
Classified in: Health
Subjects: PDT, FDA

Purolite® Protein A Chromatography Resin Implemented Into FDA-approved Commercial Manufacturing of Monoclonal Antibody Treatments


CARDIFF, Wales, March 5, 2020 /CNW/ -- Purolite Ltd., a leading manufacturer of resin-based separation, purification and extraction technologies, today announces that Praesto® Jetted A50, an agarose-based Protein A chromatography resin, has been incorporated into the commercial manufacturing process of an FDA-approved monoclonal antibody treatment by one of the world's leading contract manufacturing organizations.

Praesto resins are an integral technology used by biopharmaceutical developers for the purification of modern medicines for the treatment of cancer, rheumatoid arthritis, dementia and diabetes. Praesto Jetted A50, launched in April 2018, is Purolite's "best-in-class" Protein A chromatography resin, utilizing a patented "Jetting" manufacturing technology for uniform resin beads, a highly desirable characteristic for chromatographic applications.

Chris Major, Global Sales and Marketing Director for the Agarose division of Purolite Life Sciences, comments, "This is another milestone and a proud achievement for Purolite Life Sciences. Praesto Jetted A50 is the only commercially available Protein A resin to offer uniform beads, a feat only achievable through Purolite's proprietary Jetting technology. Praesto resins are currently incorporated into over 200 PI ? PIII clinical trials and resin screening projects globally, and we supply 10 of the world's largest biopharmaceutical developers and CMOs. For major global organisations to be recognising and adopting the extensive benefits of Jetting less than two years after launch is testament to our commitment and success in bringing forward-thinking, practical antibody purification solutions into what was previously a stagnant marketplace."

"Purolite has invested over $150 million into a global innovation program in recent years, including doubling the production capacity of our Jetting technology to facilitate growing demand. With this expansion we look forward to continuing to meet customer requirements for improved security of supply, reduced lead times and high-performance of modern Protein A resins."

Logo - https://mma.prnewswire.com/media/753768/Purolite_Life_Sciences_Logo.jpg

 

SOURCE Purolite Life Sciences


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: